Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

370
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
370
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

564
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
564

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025
Same author

Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms.

Drugs·2025
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Jul 27, 2025

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

843

格洛菲他马布:首次获得批准

Matt Shirley1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|June 7, 2023
PubMed
概括
此摘要是机器生成的。

格洛菲他马布 (Columvi®) 是一种在加拿大批准用于复发或耐火性扩散大B细胞淋巴瘤 (DLBCL) 的双特异性抗体. 这一里程碑标志着治疗无法接受CAR T细胞治疗的患者的重大进展.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.4K

相关实验视频

Last Updated: Jul 27, 2025

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

843
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.4K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 格洛菲他马布是一种新的CD20 x CD3双特异性T细胞参与的单克隆抗体.
  • 它针对B细胞非霍奇金淋巴瘤,包括扩散性大B细胞淋巴瘤 (DLBCL).

研究的目的:

  • 总结 glofitamab.b. 开发中的关键里程碑.
  • 为了突出药物的第一个有条件批准复发或耐药DLBCL.

主要方法:

  • 对glofitamab的临床发展里程碑的审查.
  • 对监管机构提交和批准的分析.

主要成果:

  • 格洛菲他马布于2023年3月25日在加拿大获得特定DLBCL患者群体的条件批准.
  • 欧盟和美国正在进行监管审查,欧盟获得了积极的意见.

结论:

  • 批准代表了治疗复发性或耐火性DLBCL的重要一步,特别是在不适合CAR T细胞治疗的患者中.
  • 目前正在进行的临床开发旨在进一步确定glofitamab在治疗各种非霍奇金淋巴瘤中的作用.